This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Parece and Urs Wiedemann published an article in the April issue of Pharmaceutical Executive. The authors discuss outcomes-based, risk-sharing agreements as one approach to change the dialogue between manufacturers and payers, from price to value. To read the article, click the link below.
Read the key takeaways here.
Several pivotal topics emerged, establishing predominant themes throughout the conference. Although efficacy continues to be the fundamental basis of oncology...
Is Going to a Private-Equity Owned Hospital Bad for Your Health? Private equity investment in health care has increased more than 20-fold—from $5 billion in...
Erin McDermott moderates the session exploring practical strategies for balancing caregiving responsibilities with professional goals. Caring for a parent,...
